ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
March 2026
Nuclear Technology
February 2026
Fusion Science and Technology
April 2026
Latest News
NRC approves TerraPower construction permit
Today, the Nuclear Regulatory Commission announced that it has approved TerraPower’s construction permit application for Kemmerer Unit 1, the company’s first deployment of Natrium, its flagship sodium fast reactor.
This approval is a significant milestone on three fronts. For TerraPower, it represents another step forward in demonstrating its technology. For the Department of Energy, it reflects progress (despite delays) for the Advanced Reactor Demonstration Program (ARDP). For the NRC, it is the first approval granted to a commercial reactor in nearly a decade—and the first approval of a commercial non–light water reactor in more than 40 years.
Florent Martinetti, Laurent Donadille, Sabine Delacroix, Catherine Nauraye, Aurélien De Oliveira, Joël Herault, Isabelle Clairand
Nuclear Technology | Volume 168 | Number 3 | December 2009 | Pages 721-727
Proton Therapy | Special Issue on the 11th International Conference on Radiation Shielding and the 15th Topical Meeting of the Radiation Protection and Shielding Division (PART 3) / Radiation Protection | doi.org/10.13182/NT09-A9296
Articles are hosted by Taylor and Francis Online.
A Monte Carlo modeling tool was applied at the Institut-Curie Centre de Protonthérapie d'Orsay, France, to simulate the passively scattered beam line used for treatment of ocular melanoma. The primary aim of this study is to validate the model for subsequent calculation of patient doses due to secondary neutrons.The Monte Carlo code MCNPX is used here to model the geometry of the beam line. The beam parameters at the entrance of the ophthalmologic beam line are not well known (beam emittance, lateral distribution, and energy spread). Hence, to accurately implement the beam source in the model, we need to calculate and measure these parameters in the first step of this study. Then, we perform comparisons between calculated and measured proton absorbed dose profiles under various scattering conditions.Comparisons between calculated and measured depth versus dose profiles show discrepancies <0.6 mm (range) and <1.1 mm (beam size and penumbra) for the lateral dose profiles. Hence, calculated relative dose profiles are considered to be correctly described by the Monte Carlo model. Some improvements are still needed to reproduce absolute dose profiles. This study should lead to the use of the numerical model for radiation protection applications.